Browse the evidence

Obesity promotes the onset of atrial fibrillation (AF) through several pathways.

Understanding these pathways can help in developing targeted interventions for AF in obese patients.

Gastrointestinal tract adverse events were reported by 63.4% of participants on semaglutide.

Practitioners should monitor for gastrointestinal side effects in patients taking semaglutide.

The prevalence of obesity among youth with type 1 diabetes increased from 18.1% to 26.0% from 2008-2011 to 2020-2023.

Healthcare providers should be aware of the rising obesity rates in youth with T1D for better management strategies.

The prevalence of obesity among adults with type 1 diabetes rose from 30.5% to 38.1% from 2008-2011 to 2020-2023.

Healthcare providers should recognize the increasing obesity rates in adults with T1D for effective treatment planning.

GLP-1RA prescriptions significantly increased across all BMI categories among youth and adults with type 1 diabetes over the last 15 years.

Clinicians should consider the increasing use of GLP-1RAs in managing obesity in T1D patients.

GLP-1RAs may have little or no effect on breast cancer risk.

Practitioners should consider that GLP-1RAs may not significantly increase breast cancer risk based on current evidence.

GLP-1RAs and dual GLP-1/GIPRA are associated with notable reductions in fat-free mass (FFM).

Practitioners should monitor FFM loss in patients undergoing GLP-1RA and GLP-1/GIPRA therapies.

A new sub-specialty, Cardiovascular-Endocrine-Metabolic Medicine, is proposed to unify care across multiple specialties.

Healthcare systems should consider integrating this new sub-specialty for improved patient outcomes.

By the fifth month, nearly one-half (46%) of semaglutide users had discontinued the treatment.

Practitioners should be aware of the high discontinuation rates when prescribing semaglutide.

Higher discontinuation rates were associated with lower household income and education level.

Socioeconomic factors should be considered when evaluating patient adherence to semaglutide.

Allodynia was observed in 4 patients associated with dose escalation of semaglutide.

Clinicians should be aware of the potential for allodynia in patients taking semaglutide.

Therapy was stopped in 2 patients, both of whom had resolution of symptoms.

Stopping semaglutide may resolve allodynia symptoms in affected patients.

Two patients opted to continue semaglutide despite the adverse effect, with one experiencing resolution after 4 months.

Some patients may choose to continue semaglutide, and symptom resolution can occur over time.

Current anti-obesity drugs have limitations regarding efficacy, side effects, weight regain, and high costs.

Awareness of these limitations can guide practitioners in seeking innovative treatment options.

The review focuses on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in the context of anti-obesity drug discovery.

Practitioners should consider the role of GLP-1 RAs in developing new anti-obesity therapies.

Excessive consumption of industrial seed oils rich in linoleic acid contributes to mitochondrial dysfunction.

Reducing intake of linoleic acid-rich oils may be beneficial for mitochondrial health.

LA-induced mitochondrial perturbations are linked with gut dysbiosis.

Addressing mitochondrial health may also improve gut microbiome balance.

Strategic dietary modulation, particularly a marked reduction in LA intake, may restore mitochondrial redox homeostasis and improve metabolic health.

Reducing linoleic acid in the diet could enhance mitochondrial function and overall metabolic health.

Postoperative weight regain (WR) affects 20-30% of patients after bariatric surgery.

Clinicians should be aware that a significant portion of bariatric surgery patients may experience weight regain.

Weight regain is influenced by hormonal adaptations, including ghrelin rebound and leptin resistance.

Understanding hormonal influences can help in developing targeted interventions for weight management post-surgery.

Gastrointestinal side effects from tirzepatide are common but mild to moderate, with less than 5% treatment discontinuation.

Practitioners should be aware of potential mild gastrointestinal side effects when prescribing tirzepatide.

GLP-1ra users have similar postoperative outcomes following body contouring surgery compared to non-GLP-1ra controls.

Practitioners can consider GLP-1ra use as not adversely affecting postoperative outcomes in body contouring surgeries.

Postoperative cellulitis occurred less frequently among GLP-1ra users in matched cohorts.

GLP-1ra use may be associated with a lower risk of postoperative cellulitis.

Wound dehiscence is more prevalent among patients taking GLP-1ras for diabetes compared to those using it for weight loss.

Consideration of the indication for GLP-1ra use may be important in assessing surgical risk.